Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.53 |
| ▸ | GHSR | Q92847 | 7/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | KHK | P50053 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12663143 | 1.00 | BPTF (0.53) | BPTFGHSRALOX5GAAG6PD | |
| SCHEMBL8125251 | 0.85 | BPTF (0.44) | BPTFGHSRALOX5GAAG6PD | |
| SCHEMBL81695 | 0.81 | ADRB1 (0.48) | GHSRADRB1KMT2ACHRNA3MEN1 | |
| SCHEMBL81349 | 0.81 | ADRB1 (0.48) | GHSRADRB1KMT2ACHRNA3MEN1 | |
| SCHEMBL19139371 | 0.79 | BPTF (0.54) | BPTFALOX5GAAG6PDL3MBTL1 | |
| SCHEMBL16069835 | 0.79 | MAPT (0.47) | GHSRGAAL3MBTL1SIGMAR1KMT2A | |
| SCHEMBL2549111 | 0.79 | GHSR (0.53) | GHSRSIGMAR1KMT2ALMNAHTT | |
| SCHEMBL12499501 | 0.79 | CDK4 (0.45) | GHSRHTT | |
| SCHEMBL3528425 | 0.79 | MAPT (0.47) | GHSRGAAL3MBTL1SIGMAR1KMT2A | |
| SCHEMBL6367230 | 0.79 | HTR3E (0.47) | GHSRSIGMAR1HTR3EHTR3BADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3124482-B1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-09-11 | — | — | EP | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| EP-3124482-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-02-01 | — | — | EP | disclosed |
| US-20160067244-A1 | Treatment for Neurological and Mental Disorders | PSYCHOGENICS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | disclosed |
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | disclosed |
| US-20140066455-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-20120070494-A1 | Treatment for Attention-Deficit Hyperactivity Disorder | PSYCHOGENICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2125748-B1 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110053956-A1 | Treatment for Neurological and Mental Disorders | PSYCHOGENICS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110008425-A1 | Treatment for Attention-Deficit Hyperactivity Disorder | PSYCHOGENICS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20090298850-A1 | Treatment for Neurological and Mental Disorders | PSYCHOGENICS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-7557109-B2 | Treatment for attention-deficit hyperactivity disorder | PSYCHOGENICS, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090104261-A1 | Treatment for Attention-Deficit Hyperactivity Disorder | PSYCHOGENICS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-7504395-B2 | Treatment for attention-deficit hyperactivity disorder | PSYCHOGENICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090104261-A1 | Treatment for Attention-Deficit Hyperactivity Disorder | SLC6A2, SLC18A2, SLC6A3 | BPTF 3398/4885GHSR 82/4885ALOX5 324/4885 |
| US-20110053956-A1 | Treatment for Neurological and Mental Disorders | PNMT, COMT, ACHE | BPTF 4506/4885GHSR 64/4885ALOX5 1674/4885 |
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | BPTF 1666/4885GHSR 1586/4885ALOX5 2101/4885 |
| US-20090298850-A1 | Treatment for Neurological and Mental Disorders | PNMT, COMT, ACHE | BPTF 4506/4885GHSR 64/4885ALOX5 1674/4885 |
| US-20120070494-A1 | Treatment for Attention-Deficit Hyperactivity Disorder | SLC6A2, SLC18A2, SLC6A3 | BPTF 3398/4885GHSR 82/4885ALOX5 324/4885 |
| US-20140066455-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | BPTF 1459/4885GHSR 1418/4885ALOX5 2922/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | BPTF 1459/4885GHSR 1418/4885ALOX5 2922/4885 |
| US-20110008425-A1 | Treatment for Attention-Deficit Hyperactivity Disorder | SLC6A2, SLC18A2, SLC6A3 | BPTF 3398/4885GHSR 82/4885ALOX5 324/4885 |
| US-20160067244-A1 | Treatment for Neurological and Mental Disorders | PNMT, COMT, ACHE | BPTF 4506/4885GHSR 64/4885ALOX5 1674/4885 |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | AXL, FLT3, TYRO3 | BPTF 1971/4885GHSR 850/4885ALOX5 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.